Schedule Of Loss And The Weighted Average Number Of Ordinary Shares Abstract Numerator: Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract] Net loss applicable to shareholders of ordinary shares Net loss Net loss Net Income (Loss) Attributable to Parent Impairment loss on investment in warrants The amount of the company invested in warrants, their value fell, and the company recorded the loss in value. Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Number of ordinary shares used in computing basic net loss per share (in Shares) Weighted average number of shares of ordinary share used in computing basic net loss per share (in Shares) Weighted Average Number of Shares Outstanding, Basic Investment in warrants Investment in warrants Investment in warrants beginning balance Investment in warrants ending balance Investment in Warrants Investment in Warrants. Investment in Shares and Warrants [Abstract] INVESTMENT IN SHARES AND WARRANTS Investment [Text Block] April 2026 Warrants [Member] Investment in shares Investment in shares ending balance Investment in shares beginning balance Investment in shares Finance income for revaluation of the investment Finance Income For Revaluation Of The Investment Amount of finance income for revaluation of the investment. Net loss per share of ordinary share, diluted (in Dollars per share) Diluted net loss per share (in Dollars per share) Earnings Per Share, Diluted Schedule Of Computation Of Diluted Net Loss Per Share Abstract Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Options [Member] Options Member IPO Warrants [Member] IPOWarrants Member Series A Warrants [Member] Series AWarrants Member Exchange Warrants [Member] Exchange Warrants Member Schedule of Computation of Diluted Net Loss Per Share [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Fair Value of Investment in Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Changes in Investment Investment [Table Text Block] Number of ordinary shares used in computing diluted net loss per share (in Shares) Weighted average number of shares of ordinary share used in computing diluted net loss per share (in Shares) Weighted Average Number of Shares Outstanding, Diluted Net loss per share of ordinary share, basic (in Dollars per share) Basic net loss per share (in Dollars per share) Earnings Per Share, Basic Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Quantum X Labs Inc. [Member] Purchase shares (in Shares) Sale of shares Registered direct offering shares Sale of Stock, Number of Shares Issued in Transaction Investment Investments, Total Warrant exercise price (in Dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercisable (in Shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of ordinary shares received upon warrant exercise Number of ordinary shares received upon warrant exercise. Investment Income [Table] Investment in Shares and Warrants [Line Items] Net Investment Income [Line Items] Fair value revaluation of investment in shares and warrants Fair value revaluation of investment in shares and warrants Fair Value Revaluation Of Investment In Shares And Warrants Amount of fair value revaluation of investment in shares and warrants. Loss Per Share [Abstract] LOSS PER SHARE Earnings Per Share [Text Block] Financial Income, Net [Abstract] Issuance of shares, warrants and pre-funded warrants, net (see Note 5) Stock Issued During Period, Value, Issued for Services Long term deposit Deposits Assets, Noncurrent Total long term assets Assets, Noncurrent, Total Payment for warrants exercised Payments to Acquire Investments, Total Ordinary shares, shares authorized (in Shares) Common Stock, Shares Authorized Ordinary shares, shares issued (in Shares) Shares issued Common Stock, Shares, Issued Ordinary shares, shares outstanding (in Shares) Common Stock, Shares, Outstanding Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense General and administrative expenses General and Administrative Expense Operating loss Operating Income (Loss) Financial income, net Financial income, net Other Nonoperating Income (Expense) Issuance of shares, warrants and pre-funded warrants, net (see Note 5) (in Shares) Issued service shares Stock Issued During Period, Shares, Issued for Services Exercise of warrants Stock Issued During Period Value Issued For Exerciseof Warrants Represent the amount of exercise of warrants. Exercise of warrants (in Shares) Stock Issued During Period Shares Issued For Exerciseof Warrants Number of exercise of warrants. Balance Total shareholders’ equity Balance Equity, Attributable to Parent Balance (in Shares) Balance (in Shares) Shares, Outstanding Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amendment Flag Amendment Flag Employees and payroll-related liabilities Employee-related Liabilities, Current Other payables and accrued expenses Accounts Payable and Accrued Liabilities, Current Total current liabilities Liabilities, Current Shareholders’ equity: Temporary Equity [Abstract] Ordinary shares, no par value per share; Authorized: 2,000,000,000 shares as of June 30, 2026 and December 31, 2025; Issued and outstanding: 2,125,659 and 1,608,266 shares as of June 30, 2026, and December 31, 2025, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total liabilities and shareholders’ equity Liabilities and Equity Statement of Financial Position [Abstract] Ordinary shares, par value (in Dollars per share) Common Stock, Par or Stated Value Per Share Ordinary shares Ordinary Shares [Member] Common Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated deficit Retained Earnings [Member] Document Information [Line Items] Entity Central Index Key Entity Central Index Key Document Type Document Type Document Fiscal Year Focus Document Fiscal Year Focus Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Sale of Stock [Axis] Sale of Stock [Domain] Offering [Member] IPO [Member] IPO [Member] Private Placement [Member] Private Placement [Member] Purchase price per unit (in Dollars per share) Sale of Stock, Price Per Share Equity Components [Axis] Equity Component [Domain] Document Period End Date Document Period End Date Statement [Line Items] Share based payment APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share based payment (in Shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture FINANCIAL INCOME, NET Other Nonoperating Income and Expense [Text Block] Subsequent Events [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] Significant Accounting Policies [Abstract] Unaudited consolidated financial statements Unaudited Consolidated Financial Statements [Policy Text Block] Disclosure of accounting policy for unaudited financial statement. Cover [Abstract] Document Information [Table] Current liabilities: Liabilities, Current [Abstract] Schedule of Expenses Recognized [Line Items] Total Share based expense Share-Based Payment Arrangement, Expense Warrants issued upon IPO (in Shares) Stock Issued During Period, Shares, New Issues Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Phase 3 Clinical Trials [Member] Phase3 Clinical Trials Member FDA [Member] FDAMember EU Regulatory Body [Member] EURegulatory Body Member Additional Jurisdiction Clinical [Member] Additional Jurisdiction Clinical Member Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] License Agreement [Member] License Agreement Member Related Party Transaction [Axis] Related Party Transaction [Domain] SciSparc [Member] Sci Sparc Member Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Pre-Funded Warrants [Member] Pre-Funded Warrants [Member] Pre Funded Warrants Member Warrants [Member] Warrant [Member] Finite-Lived Intangible Assets by Major Class [Axis] Number of ordinary shares received NumberOfOrdinarySharesReceived Number of ordinary shares received. Number of shares grant in period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Statement Of Income Locations Balance [Axis] Income Statement Locations [Domain] Research and development expenses [Member] General and administrative expenses [Member] Product and Service [Axis] Product and Service [Domain] Service [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] License [Member] License [Member] Intangible Asset, Net [Line Items] Achievement of milestones Payments for Purchase of Other Assets Shareholders’ Equity [Line Items] Number of warrants exercised Class of Warrant or Right, Number of Securities Called by Warrants or Rights Proceeds from issuance of private placement (in Dollars) Proceeds from Issuance of Private Placement Proceeds issuance costs (in Dollars) Proceeds from Debt, Net of Issuance Costs PIPE pre-funded warrants [Member] Product basis rate Product Basis Rate Percentage of product basis rate. Proceedings of equity Proceeds from Issuance or Sale of Equity Percentage of sublicenses Percentage Of Sublicenses Percentage of sublicenses. Ordinary shares issued (in Shares) Stock Issued During Period, Shares, Other Issued initial public offering Proceeds from Issuance Initial Public Offering Fair value of shares committed to be issued Fair Value Of Shares To Be Issued Fair value of commitment shares to be issued. Estimate useful life Finite-Lived Intangible Asset, Useful Life Intangible asset impairment loss Impairment of Intangible Assets (Excluding Goodwill) Consultants [Member] Prefunded Warrants Prefunded Warrants Number of prefunded warrants. Warrants outstanding Warrants shares (in Shares) Class of Warrant or Right, Outstanding Ordinary shares ratio Stockholders' Equity Note, Stock Split Ordinary held share Ordinary Held Share The number of ordinary held share. Recently accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible Asset, Net [Abstract] Taurus Gold Corp [Member] Taurus Gold Corp [Member] Class of Stock [Axis] Class of Stock [Domain] Purchase units (in Shares) Units Purchase Shares Units Purchase Shares. Warrants issuance costs (in Dollars) Proceeds from Issuance of Warrants Investment, Name [Axis] Investment, Name [Domain] Fair value of investment Warrants and Rights Outstanding, Measurement Input Fair Value, by Balance Sheet Grouping [Table] Schedule of Fair Value of Investment in Warrants [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Measurement Input Type [Axis] Measurement Input Type [Domain] Share price [Member] Measurement Input, Share Price [Member] Volatility [Member] Measurement Input, Price Volatility [Member] Interest rate [Member] Measurement Input, Risk Free Interest Rate [Member] Term (years) [Member] Measurement Input, Expected Term [Member] Number of warrants [Member] Measurement Input Number Of Warrants Member Warrant term Warrants and Rights Outstanding, Term Fair value [Member] Measurement Input Fair Value Member Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Purchase of shares Amount of purchase of shares. Changes in fair value Changes In Fair Value Investment In Shares Amount of changes in fair value investment in shares. Changes in fair value Changes In Fair Value Investment In Warrants Amount of changes in fair value investment in warrants. Purchase of warrants Purchase Of Warrants Amount of purchase of warrants. Gross proceeds Gross Proceeds from Offering and Private Placement The cash inflow of offering and private placemen Net of issuance costs Debt Issuance Costs, Net, Total PIPE Ordinary Warrants [Member] PIPE Ordinary Warrants [Member] Scenario [Axis] Scenario [Domain] Forecast [Member] Schedule of Financial Income, Net [Abstract] Fair value revaluation of warrant liability Fair value revaluation of warrant liability Liabilities, Fair Value Adjustment Interest income from short term deposits Interest Income, Short-Term Investment, Other Exchange rate differences Exchange Rate Differences In Financial Income The amount of Exchange rate differences in financial income. Finance expenses Other Nonoperating Expense Bank fees Bank Fees Represents the amount of bank fees. Gross proceeds Proceeds from issuance of ordinary shares, warrants and pre-funded warrants Proceeds from Issuance of Common Stock Document Fiscal Period Focus Document Fiscal Period Focus Short term deposit Deposits Assets, Current Maturity of short term deposit Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total Investment in shares and warrants Investment in shares and warrants Amount of investment in shares and warrants. Subsequent Event [Table] Subsequent Events [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible asset, net Balance Balance Intangible Assets, Net (Excluding Goodwill) Total assets Assets Depreciation and amortization Depreciation Share based payment Share-Based Payment Arrangement, Noncash Expense Finance expenses Financing Interest Expense Change in: Increase (Decrease) in Operating Assets [Abstract] Other current assets Increase (Decrease) in Other Current Assets Employees and payroll-related liabilities Increase (Decrease) in Employee Related Liabilities Other payables and accrued expenses Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Issuance of shares (RSU) Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of shares (RSU) (in Shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Statement of Stockholders' Equity [Abstract] Statement [Table] Non-cash financing activities: Noncash Investing and Financing Items [Abstract] Exercise of warrants into ordinary shares Exercise Of Warrants Into Ordinary Shares Exercise of warrants into ordinary shares. IPO warrants exchange IPOWarrants Exchange IPO warrants exchange. General [Abstract] GENERAL Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] INTANGIBLE ASSET, NET Intangible Assets Disclosure [Text Block] Shareholders’ Equity [Abstract] SHAREHOLDERS’ EQUITY Equity [Text Block] Schedule of Loss and the Weighted Average Number of Ordinary Shares Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Financial Income, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of Changes in the Carrying Amount of the Company’s Intangible Assets [Abstract] Amortization Amortization of Intangible Assets Impairment Other Asset Impairment Charges Schedule Of Expenses Recognized Abstract Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Amortization expense for intangible assets Finite-Lived Intangible Assets, Net Shareholders’ Equity (Details) [Table] Plan Name [Axis] Plan Name [Domain] 2021 Plan [Member] Two Thousand Twenty One Plan Member Title and Position [Axis] Title and Position [Domain] Chief Executive Officer [Member] Chief Executive Officer [Member] Award Type [Axis] Award Type [Domain] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Schedule of Changes in the Carrying Amount of The Company’s Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Expenses Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Intangible Asset, Net (Details) [Table] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Preclinical safety test [Member] Preclinical Safety Test Member Phase I Clinical Trial [Member] Phase1 Clinical Trial Member Phase 2a Clinical Trial [Member] Phase2a Clinical Trial Member Phase 2b Clinical Trial [Member] Phase2b Clinical Trial Member Additional ordinary shares issued Additional Ordinary Shares Number of additional ordinary shares. Reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Grant options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Restricted stock units granted fair value (in Dollars) Restricted Stock Units Granted Fair Value The amount of restricted stock units granted fair value.